Black Diamond Therapeutics, Inc.
NASDAQ:BDTXBiotechnology
-$0.04 today
- Market cap
- $82.18M
- Beta
- 3.23
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$0.75
Volume 0.60M
Average 1.31M
BDTX Interest Income
Income earned on cash, deposits, and investments held by the company.
Black Diamond Therapeutics, Inc.NASDAQ: BDTX
Interest Income · Q1 FY2026 · quarter ended Mar 2026
Interest income grows, but more slowly than its trailing trend
Q1 FY2026 interest income of $1.02M rose 71.9% year over year, behind the +109.8% change in trailing-twelve-month interest income. Sequentially, it fell 13.6% from the prior quarter. Over 3 fiscal years it compounded at +26.0% a year.
Context
- Interest income amounted to 5.8% of revenue in FY2025.
- Interest income increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +71.9% toward the trailing-twelve-month pace of +109.8%.
Sources:Income StatementText generated from reported figures; not investment advice.
Interest Income history
USD · from the income statement
- Latest · FY2025
- 4.06M USD
- Year-over-year change
- +86.1%
- 4-year CAGR
- +4.1%
| Period | Period end | Interest Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.06M | +86.1% |
| FY2024 | 2024-12-31 | 2.18M | +13.4% |
| FY2023 | 2023-12-31 | 1.92M | -5.3% |
| FY2022 | 2022-12-31 | 2.03M | -41.4% |
| FY2021 | 2021-12-31 | 3.46M | — |
Interest Income vs competitors
How BDTX compares with its peers on the latest reported figures
- Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +109.8% is the 2nd highest of 10, against a peer median of -24.3%.
- Over three fiscal years its annual growth of +26.0% compares with a peer median of +59.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $8.9M USD | -24.3% | +82.0% | 12.9% | |
| LTM Mar 2026 | $7.8M USD | -35.9% | +15.5% | 27.6% | |
| LTM Mar 2026 | $5.6M USD | +18.8% | +134.5% | 38.5% | |
| LTM Mar 2026 | $4.85M USD | +39.2% | +249.9% | — | |
| LTM Mar 2026 | $4.49M USD | +109.8% | +26.0% | — | |
| LTM Mar 2026 | $4.01M USD | -8.1% | — | 6803.4% | |
| LTM Mar 2026 | $2.84M USD | -27.6% | +11.1% | 1262.2% | |
| FY2025 | €2.83M EUR | +147.5% | +93.6% | 63.1% | |
| LTM Mar 2026 | $892.82K USD | -47.3% | +59.2% | 1.8% | |
| LTM Mar 2026 | $0 USD | — | +20.3% | 0.0% | |
| LTM Mar 2026 | -$411.45M USD | -18576.2% | +44.2% | — | |
| Peer median (excluding BDTX) | — | -24.3% | +59.2% | 33.1% | |
Competitors are the stored peer set for BDTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 70M |
| Cost of Revenue | 0 | 0 | 437K | 0 | 325K |
| Gross Profit | 0 | 0 | (437K) | 0 | 69.68M |
| Gross Margin | — | — | — | — | 99.5% |
| Research & Development | 96.83M | 64.44M | 58.91M | 51.31M | 33.56M |
| Selling, General & Admin | 30.04M | 28.39M | 27.11M | 27.47M | 16.57M |
| Operating Expenses | 126.87M | 92.83M | 86.02M | 78.78M | 49.81M |
| Depreciation & Amortization | 205K | 508K | 437K | 343K | 325K |
| EBITDA | (125.39M) | (90.66M) | (82.01M) | (69.33M) | 22.69M |
| EBITDA Margin | — | — | — | — | 32.4% |
| Operating Income | (126.87M) | (92.83M) | (86.46M) | (78.78M) | 19.87M |
| Operating Margin | — | — | — | — | 28.4% |
| Interest Income | 3.46M | 2.03M | 1.92M | 2.18M | 4.06M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.28M | 1.66M | 4.02M | 9.11M | 2.5M |
| Income Before Tax | (125.6M) | (91.17M) | (82.44M) | (69.68M) | 22.37M |
| Pre-Tax Margin | — | — | — | — | 32.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (125.6M) | (91.17M) | (82.44M) | (69.68M) | 22.37M |
| Net Margin | — | — | — | — | 32.0% |
| EPS (Basic) | (3.47) | (2.52) | (1.88) | (1.27) | 0.39 |
| EPS (Diluted) | (3.47) | (2.52) | (1.88) | (1.27) | 0.39 |
| Weighted Avg Shares | 36.19M | 36.23M | 43.95M | 55.03M | 56.87M |
| Weighted Avg Shares (Diluted) | 36.19M | 36.23M | 43.95M | 55.03M | 57.56M |
Black Diamond Therapeutics, Inc.
NASDAQ:BDTX
Intrinsic Alpha fair value
Locked
Current Price
$1.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.